5 reports of this reaction
16.7% of all CHELIDONIUM MAJUS reports
#2 most reported adverse reaction
ACUTE KIDNEY INJURY is the #2 most commonly reported adverse reaction for CHELIDONIUM MAJUS, manufactured by BM Private Limited. There are 5 FDA adverse event reports linking CHELIDONIUM MAJUS to ACUTE KIDNEY INJURY. This represents approximately 16.7% of all 30 adverse event reports for this drug.
Patients taking CHELIDONIUM MAJUS who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is a frequently reported adverse event for CHELIDONIUM MAJUS, accounting for a significant proportion of all reports.
In addition to acute kidney injury, the following adverse reactions have been reported for CHELIDONIUM MAJUS:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 5 FDA reports for CHELIDONIUM MAJUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 16.7% of all adverse event reports for CHELIDONIUM MAJUS, making it one of the most commonly reported side effect.
If you experience acute kidney injury while taking CHELIDONIUM MAJUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.